NCT07166094View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

544

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

February 28, 2029

Conditions
Endometrial CancerRecurrent or Progressive Endometrial Cancer
Interventions
DRUG

Rina-S

Intravenous (IV) infusion.

DRUG

IC

"* Paclitaxel: IV infusion~* Doxorubicin: IV bolus injection/infusion"

Sponsors

Lead Sponsor

Genmab
All Listed Sponsors
lead

Genmab

INDUSTRY